Enrollment For Phase 3 Trial Evaluating Azeliragon In Treatment Of Patients With Mild Alzheimer's Disease
Sunday, May 24, 2015 - 12:40
in Health & Medicine
Enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease has begun. Phase 3 begins following a Phase 2 trial that demonstrated positive results in slowing cognitive decline with 5 mg/day of azeliragon in patients with mild to moderate Alzheimer's Disease. read more